Skip to main content
SpringerLink
Log in

The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury

  • Original Contribution
  • Published:
Basic Research in Cardiology Aims and scope Submit manuscript

Abstract

Nitric oxide (NO) is an important regulator of vascular and myocardial function. Cardiac ischemia/reperfusion injury is reduced in mice overexpressing endothelial NO synthase (eNOS) suggesting cardioprotection by eNOS. Novel pharmacological substances, so called eNOS enhancers, upregulate eNOS expression and thereby increase NO production. We tested the effects of the eNOS enhancer AVE 9488 on cardiac ischemia/reperfusion injury in vivo in mice. After treatment with the eNOS enhancer AVE 9488 (30 mg/kg/day) or placebo for one week mice underwent 30 min of coronary artery ligation and 24 h of reperfusion in vivo. Ischemia-reperfusion damage was significantly reduced in mice treated with the eNOS enhancer when compared to placebo treated mice (infarct/area at risk 65.4 ± 4.1 vs. 36.9 ± 4.0%, placebo vs. eNOS enhancer, P = 0.0002). The protective effect was blunted in eNOS knockout mice treated with the eNOS enhancer (infarct/area at risk 64.1 ± 6.2%, eNOS knockout + eNOS enhancer vs. WT + eNOS enhancer, P = ns). Reactive oxygen species were significantly reduced in mice treated with the eNOS enhancer as indicated by significantly lower malondialdehyde–thiobarbituric acid levels (placebo vs. eNOS enhancer, 3.2 ± 0.5 vs. 0.8 ± 0.07 μmol/l, P = 0.0003). Thus pharmacological interventions addressed to increase eNOS-derived NO production constitute a promising therapeutic approach to prevent myocardial ischemia/reperfusion injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Adamek A, Hu K, Bayer B, Wagner H, Ertl G, Bauersachs J, Frantz S (2007) High dose aspirin and left ventricular remodeling after myocardial infarction. Bas Res Cardiol 102:334–340

    Article  CAS  Google Scholar 

  2. Bauersachs J, Bouloumie A, Fraccarollo D, Hu K, Busse R, Ertl G (1999) Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression: role of enhanced vascular superoxide production. Circulation 100:292–298

    CAS  PubMed  Google Scholar 

  3. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G (2001) Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104:982–985

    Article  CAS  PubMed  Google Scholar 

  4. Becker LB (2004) New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 61:461–470

    Article  CAS  PubMed  Google Scholar 

  5. Calvert JW, Lefer DJ (2009) Myocardial protection by nitrite. Cardiovasc Res (in press)

  6. Duranski MR, Greer JJ, Dejam A, Jaganmohan S, Hogg N, Langston W, Patel RP, Yet SF, Wang X, Kevil CG, Gladwin MT, Lefer DJ (2005) Cytoprotective effects of nitrite during in vivo ischemia-reperfusion of the heart and liver. J Clin Invest 115:1232–1240

    CAS  PubMed  Google Scholar 

  7. Feng Q, Lu X, Jones DL, Shen J, Arnold JM (2001) Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104:700–704

    Article  CAS  PubMed  Google Scholar 

  8. Fleming I, Busse R (2003) Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 284:R1–12

    CAS  PubMed  Google Scholar 

  9. Forstermann U, Munzel T (2006) Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113:1708–1714

    Article  PubMed  Google Scholar 

  10. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J (2003) Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Col Cardiol 42:1666–1673

    Article  CAS  Google Scholar 

  11. Fraccarollo D, Widder JD, Galuppo P, Thum T, Tsikas D, Hoffmann M, Ruetten H, Ertl G, Bauersachs J (2008) Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction. Circulation 118:818–827

    Article  CAS  PubMed  Google Scholar 

  12. Frantz S, Calvillo L, Tillmanns J, Elbing I, Dienesch C, Bischoff H, Ertl G, Bauersachs J (2005) Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury. Prevention by the alpha-glucosidase inhibitor Acarbose. FASEB 19:591–593

    CAS  Google Scholar 

  13. Frantz S, Hu K, Adamek A, Wolf J, Sallam A, Maier SK, Lonning S, Ling H, Ertl G, Bauersachs J (2008) Transforming growth factor beta inhibition increases mortality and left ventricular dilatation after myocardial infarction. Basic Res Cardiol 103:485–492

    Article  CAS  PubMed  Google Scholar 

  14. Frantz S, Hu K, Widder J, Bayer B, Witzel CC, Schmidt I, Galuppo P, Strotmann J, Ertl G, Bauersachs J (2004) Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 141:9–14

    Article  CAS  PubMed  Google Scholar 

  15. Frantz S, Tillmanns J, Kuhlencordt PJ, Schmidt I, Adamek A, Dienesch C, Thum T, Gerondakis S, Ertl G, Bauersachs J (2007) Tissue-specific effects of the nuclear factor kappa B subunit p50 on myocardial ischemia-reperfusion injury. Am J Pathol 171:507–512

    Article  CAS  PubMed  Google Scholar 

  16. Gonon AT, Bulhak A, Labruto F, Sjoquist PO, Pernow J (2007) Cardioprotection mediated by rosiglitazone, a peroxisome proliferator-activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 102:80–89

    Article  CAS  PubMed  Google Scholar 

  17. Heinzel FR, Gres P, Boengler K, Duschin A, Konietzka I, Rassaf T, Snedovskaya J, Meyer S, Skyschally A, Kelm M, Heusch G, Schulz R (2008) Inducible nitric oxide synthase expression and cardiomyocyte dysfunction during sustained moderate ischemia in pigs. Circ Res 103:1120–1127

    Article  CAS  PubMed  Google Scholar 

  18. Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118:1915–1919

    Article  PubMed  Google Scholar 

  19. Heusch G, Post H, Michel MC, Kelm M, Schulz R (2000) Endogenous nitric oxide and myocardial adaptation to ischemia. Circ Res 87:146–152

    CAS  PubMed  Google Scholar 

  20. Jones SP, Bolli R (2006) The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 40:16–23

    Article  CAS  PubMed  Google Scholar 

  21. Jones SP, Girod WG, Palazzo AJ, Granger DN, Grisham MB, Jourd’Heuil D, Huang PL, Lefer DJ (1999) Myocardial ischemia-reperfusion injury is exacerbated in absence of endothelial cell nitric oxide synthase. Am J Physiol 276:H1567–H1573

    CAS  PubMed  Google Scholar 

  22. Jones SP, Greer JJ, Kakkar AK, Ware PD, Turnage RH, Hicks M, van Haperen R, de Crom R, Kawashima S, Yokoyama M, Lefer DJ (2004) Endothelial nitric oxide synthase overexpression attenuates myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 286:H276–H282

    Article  CAS  PubMed  Google Scholar 

  23. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, Spiekermann S, Hilfiker-Kleiner D, Templin C, Kotlarz D, Mueller M, Fuchs M, Hornig B, Haller H, Drexler H (2004) Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110:1933–1939

    Article  CAS  PubMed  Google Scholar 

  24. Lefer DJ, Nakanishi K, Johnston WE, Vinten-Johansen J (1993) Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion of dogs. Circulation 88:2337–2350

    CAS  PubMed  Google Scholar 

  25. Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA (1996) Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension 27:7–13

    PubMed  Google Scholar 

  26. Martin C, Schulz R, Post H, Boengler K, Kelm M, Kleinbongard P, Gres P, Skyschally A, Konietzka I, Heusch G (2007) Microdialysis-based analysis of interstitial NO in situ: NO synthase-independent NO formation during myocardial ischemia. Cardiovasc Res 74:46–55

    Article  CAS  PubMed  Google Scholar 

  27. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S (1994) Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 72:561–566

    Article  CAS  PubMed  Google Scholar 

  28. Nakanishi K, Vinten-Johansen J, Lefer DJ, Zhao Z, Fowler WC 3rd, McGee DS, Johnston WE (1992) Intracoronary l-arginine during reperfusion improves endothelial function and reduces infarct size. Am J Physiol 263:H1650–H1658

    CAS  PubMed  Google Scholar 

  29. Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283:H1263–H1269

    CAS  PubMed  Google Scholar 

  30. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ, Hoke NN, Roy SK, Brown WR, Prabhakar S, Kukreja RC (2008) Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol 294:H1398–H1406

    Article  CAS  Google Scholar 

  31. Sam F, Sawyer DB, Xie Z, Chang DL, Ngoy S, Brenner DA, Siwik DA, Singh K, Apstein CS, Colucci WS (2001) Mice lacking inducible nitric oxide synthase have improved left ventricular contractile function and reduced apoptotic cell death late after myocardial infarction. Circ Res 89:351–356

    Article  CAS  PubMed  Google Scholar 

  32. Sasaki K, Heeschen C, Aicher A, Ziebart T, Honold J, Urbich C, Rossig L, Koehl U, Koyanagi M, Mohamed A, Brandes RP, Martin H, Zeiher AM, Dimmeler S (2006) Ex vivo pretreatment of bone marrow mononuclear cells with endothelial NO synthase enhancer AVE9488 enhances their functional activity for cell therapy. Proc Natl Acad Sci USA 103:14537–14541

    Article  CAS  PubMed  Google Scholar 

  33. Schafer A, Burkhardt M, Vollkommer T, Bauersachs J, Munzel T, Walter U, Smolenski A (2003) Endothelium-dependent and -independent relaxation and VASP serines 157/239 phosphorylation by cyclic nucleotide-elevating vasodilators in rat aorta. Biochem Pharmacol 65:397–405

    Article  CAS  PubMed  Google Scholar 

  34. Schafer A, Wiesmann F, Neubauer S, Eigenthaler M, Bauersachs J, Channon KM (2004) Rapid regulation of platelet activation in vivo by nitric oxide. Circulation 109:1819–1822

    Article  PubMed  Google Scholar 

  35. Schulz R, Kelm M, Heusch G (2004) Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res 61:402–413

    Article  CAS  PubMed  Google Scholar 

  36. Sharp BR, Jones SP, Rimmer DM, Lefer DJ (2002) Differential response to myocardial reperfusion injury in eNOS-deficient mice. Am J Physiol Heart Circ Physiol 282:H2422–H2426

    CAS  PubMed  Google Scholar 

  37. Treasure CB, Vita JA, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, Sutton MG, Selwyn AP, Alexander RW et al (1990) Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 81:772–779

    CAS  PubMed  Google Scholar 

  38. Trochu JN, Bouhour JB, Kaley G, Hintze TH (2000) Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 87:1108–1117

    CAS  PubMed  Google Scholar 

  39. West MB, Rokosh G, Obal D, Velayutham M, Xuan YT, Hill BG, Keith RJ, Schrader J, Guo Y, Conklin DJ, Prabhu SD, Zweier JL, Bolli R, Bhatnagar A (2008) Cardiac myocyte-specific expression of inducible nitric oxide synthase protects against ischemia/reperfusion injury by preventing mitochondrial permeability transition. Circulation 118:1970–1978

    Article  CAS  PubMed  Google Scholar 

  40. Widder JD, Chen W, Li L, Dikalov S, Thony B, Hatakeyama K, Harrison DG (2007) Regulation of tetrahydrobiopterin biosynthesis by shear stress. Circ Res 101:830–838

    Article  CAS  PubMed  Google Scholar 

  41. Wohlfart P, Xu H, Endlich A, Habermeier A, Closs EI, Hubschle T, Mang C, Strobel H, Suzuki T, Kleinert H, Forstermann U, Ruetten H, Li H (2008) Antiatherosclerotic effects of small-molecular-weight compounds enhancing endothelial nitric-oxide synthase (eNOS) expression and preventing eNOS uncoupling. J Pharmacol Exp Ther 325:370–379

    Article  CAS  PubMed  Google Scholar 

  42. Wong SH, Knight JA, Hopfer SM, Zaharia O, Leach CN Jr, Sunderman FW Jr (1987) Lipoperoxides in plasma as measured by liquid-chromatographic separation of malondialdehyde––thiobarbituric acid adduct. Clin Chem 33:214–220

    CAS  PubMed  Google Scholar 

  43. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R (2007) Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription1/3 pathway. Circulation 116:535–544

    Article  CAS  PubMed  Google Scholar 

  44. Zhao W, Fan GC, Zhang ZG, Bandyopadhyay A, Zhou X, Kranias EG (2009) Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis. Basic Res Cardiol 104:377–389

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 688, TP A10). We thank B. Bayer and H. Wagner for their excellent technical support.

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik I, Universitätsklinikum Würzburg, Josef-Schneider-Str. 2, 97080, Würzburg, Germany

    S. Frantz, A. Adamek, D. Fraccarollo, J. Tillmanns, J. D. Widder, C. Dienesch, A. Schäfer, A. Podolskaya, M. Held, G. Ertl & J. Bauersachs

  2. Sanofi-Aventis, Frankfurt, Germany

    H. Ruetten

Authors
  1. S. Frantz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Adamek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. Fraccarollo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Tillmanns
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. D. Widder
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C. Dienesch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. Schäfer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Podolskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Held
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. H. Ruetten
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. G. Ertl
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. Bauersachs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Bauersachs.

Additional information

S. Frantz and A. Adamek contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frantz, S., Adamek, A., Fraccarollo, D. et al. The eNOS enhancer AVE 9488: a novel cardioprotectant against ischemia reperfusion injury. Basic Res Cardiol 104, 773–779 (2009). https://doi.org/10.1007/s00395-009-0041-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00395-009-0041-3

Keywords

Search

Navigation